title: Multiple squamous cell carcinomas following treatment with sorafenib for renal cell carcinoma.
authors.affiliation: Department of Dermatology, Wayne State University, DearbornGeorgetown Dermatologists, Sterling HeightsPinkus Dermatopathology Laboratory, Monroe, MI, USA.
authors.forename: Abdel Kader
authors.initials: AK
authors.lastname: El Tal
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Remichofsky
authors.forename: David A
authors.initials: DA
authors.lastname: Mehregan
authors.forename: Laura K
authors.initials: LK
authors.lastname: Ganger
mesh_terms: D000368:Aged; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000473:pathology; D009536:Niacinamide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D012878:Skin Neoplasms / Q000139:chemically induced* / Q000473:pathology; D000077157:Sorafenib
chemical_list: D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D000077157:Sorafenib